UCLA Health Implements Tumor DNA Profiling Using Genomoncology’s GO Clinical Workbench
UCLA Health Implements Tumor DNA Profiling using GenomOncology’s GO Clinical Workbench in order to be able to launch and process more tests with a streamlined workflow and a full audit trail to support the CAP / CLIA guidelines.
October 13, 2015
October 13, 2015 CLEVELAND – GenomOncology today announced that UCLA Health has adopted the GO Clinical WorkbenchTM to accelerate analysis and reporting for its tumor DNA profiling tests.
UCLA Health uses next generation sequencing for tumor profiling of its lung and colorectal cancer patients and has seen increasing demand for these treatment-guiding tests. Implementing and managing next generation sequencing based tests is highly complex and can be arduous. As tumor profiling became core to routine cancer care, they needed a platform that would allow them to quickly and easily scale and expand their offerings to keep pace with rapid advances in diagnostics and targeted therapeutics.
The GO Clinical Workbench provides a step-by-step workflow for the laboratory to easily perform quality control, evaluate all the detected variants, and dynamically generate and sign out a clinical report based on validated rules. By using GenomOncology’s tools, UCLA Health will be able to launch and process more tests with assured accuracy while logging a full audit trail to support the CAP / CLIA guidelines.
GenomOncology’s GO Clinical Workbench for analysis and reporting is the flagship product within the GO Precision Medicine Portfolio™, a full suite of tools designed to help healthcare institutions implement, perform, and maximize the benefits of precision medicine. The tools are installed behind the institution’s firewall and are configured to each laboratory’s specific needs.
“Enabling institutions such as UCLA Health to streamline and expand their precision medicine operations is our central purpose at GenomOncology. Molecular pathology laboratories face many challenges, including the rapid evolution of genetics technology and practice guidelines,” said Manuel J. Glynias, President and CEO of GenomOncology. “We are delighted that yet another leading cancer center has selected our company as their partner in implementing a customized, scalable solution for tumor analysis and reporting.”
GenomOncology is a healthcare technology company enabling precision medicine by transforming genomic data into actionable information. The GO Precision Medicine Portfolio™ is trusted by molecular pathologists and medical geneticists for streamlined development and production of knowledge- and guideline-driven cancer and hereditary disease tests. GenomOncology’s technology allows multiple modes of genetic analysis to fuel integrated clinical decision support and research built on accumulating experience. Learn more at .